Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASEAN Countries Agree To Ensure All Exports Meet GMP Standards In Southeast Asia By 2011

This article was originally published in The Pink Sheet Daily

Executive Summary

Mutual recognition agreement aims to eliminate some trade barriers between countries in the Association of Southeast Asian Nations and spur development of unified manufacturing and certification standards by 2011, with the goal of creating an EU-like alliance.

You may also be interested in...



Government-funded BiotechCorp Senior VP For Healthcare Selvam Ramaraj On Malaysia’s Biotech Expansion Plans: An Interview With PharmAsia News (Part 2 of 2)

Malaysiahas identified the biotechnology industry as one of the key drivers of growth in transforming the country into a knowledge-based economy, and the government is fully committed to its development. As part of that commitment, the government set up the Malaysian Biotechnology Corporation (BiotechCorp) in 2005, as one of the action plans under the National Biotechnology Policy, under the purview of the Ministry of Science, Technology and Innovation. BiotechCorp's goal is to identify value propositions in both R&D and commerce and support these ventures via financial assistance and other means. BiotechCorp Senior Vice President for Healthcare Selvam Ramaraj recently talked with PharmAsia News about the company and its master plans for Malaysia.

Indonesia Pharma Outlook From IPMG Director Parulian Simanjuntak: An Interview With PharmAsia News

Indonesia is one of the least attractive pharma markets in Asia, with multinational companies facing major obstacles due to government restrictions and lack of transparency. Deficiencies in patent protection and a sizeable counterfeit industry make the situation even grimmer there. International Pharmaceutical Manufacturers' Group Executive Director Parulian Simanjuntak talked with PharmAsia News about the regulations that are putting a stranglehold on manufacturers in Indonesia and MNCs that might otherwise be thinking about entering Indonesia. IPMG, based in Jakarta, is the association for international pharmaceutical companies doing business in Indonesia.

Global Drug Regulators And Manufacturers Grapple With How To Ensure Global Quality Standards (Part 2 Of 2)

[Editor's note: This is part two of a two-part feature on ensuring drug quality, as discussed at the Fifth IFPMA Asian Regulatory Conference in Kuala Lumpur. Part one appeared in PharmAsia News, March 17, 2008.]

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069290

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel